Company Description
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
The company’s lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial.
In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage.
The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018.
Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Mark Velleca |
Contact Details
Address: One Main Street, 14th Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 617 252 0848 |
| Website | blackdiamondtherapeutics.com |
Stock Details
| Ticker Symbol | BDTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001701541 |
| CUSIP Number | 09203E105 |
| ISIN Number | US09203E1055 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark A. Velleca M.D., Ph.D. | Chief Executive Officer, President and Chairman |
| Dr. David M. Epstein Ph.D. | Co-Founder and Director |
| Dr. Fang Ni Pharm.D. | Advisor |
| Dr. Sergey Yurasov M.D., Ph.D. | Chief Medical Officer |
| Dr. Elizabeth Buck Ph.D. | Co-Founder and Chief Scientific Officer |
| Erika Jones | Principal Financial Officer, Principal Accounting Officer, SVice President of Finance and Corporate Controller |
| Brent Hatzis-Schoch Esq., J.D. | Chief Operating Officer and General Counsel |
| Elizabeth L. Montgomery | Chief People Officer |
| Melanie Morrison | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 7, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Aug 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 6, 2024 | 10-Q | Quarterly Report |